GS-US-592-6173-A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1.
Primary Objective:
To compare PFS as assessed by BICR between SG and pembrolizumab versus treatment of physicians choice (TPC) and pembrolizumab.
Secondary Objectives:
1. To compare OS between the 2 arms
2. To compare ORR as assessed by BICR between the 2 arms
3. To compare DOR as assessed by BICR between the 2 arms
4. To compare TTR as assessed by BICR between the 2 arms
5. To compare safety and tolerability between the 2 arms
6. To compare time to deterioration (TTD) in global health status/ quality of life (QOL), pain, and fatigue as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [Version 3.0]) between the 2 arms.
Nab-paclitaxel
Sacitzumab govitecan/IMMU-132
GEMCITABINE
PACLITAXEL
Pembrolizumab (MK-3475)
Pembrolizumab(MK-3475)
Chemotherapy single agent systemic
- Rutgers Cancer Institute of New Jersey
- RWJBarnabas Health
- Cooperman Barnabas, Livingston
- Jersey City Medical Center, Jersey City
- Monmouth Medical Center
- Robert Wood Johnson University Hospital, Hamilton
- Robert Wood Johnson University Hospital, Somerset
- Rutgers Cancer Institute of New Jersey-University Hospital
Key Inclusion Criteria
- Individuals with locally advanced, inoperable, or metastatic triple-negative breast
cancer (TNBC) who have not received previous systemic therapy for advanced disease and
whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
- Individuals must have completed treatment for Stage I to III breast cancer, if
indicated, and ≥ 6 months must have elapsed between completion of treatment with
curative intent and first documented local or distant disease recurrence.
- Individuals presenting with de novo metastatic TNBC are eligible for this study.
- TNBC status and tumor PD-L1 combined positive score (CPS) will be confirmed
centrally on a recent or archival tumor specimen.
- Individuals must have measurable disease by computed tomography (CT) or magnetic
resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors
(RECIST) Version 1.1 criteria as evaluated locally.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Demonstrates adequate organ function
- Male and female individuals of childbearing potential who engage in heterosexual
intercourse must agree to use protocol-specified method(s) of contraception.
- Individuals with HIV must be on antiretroviral therapy (ART) and have a
well-controlled HIV infection/disease.
Key Exclusion Criteria
- Positive serum pregnancy test or women who are lactating.
- Received prior therapy with an agent directed to another stimulatory or coinhibitory
T-cell receptor.
- Individuals may not have received systemic anticancer treatment (with the exception of
endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks
prior to enrollment.
- Individuals may not be participating in a study with an investigational agent or
investigational device within 4 weeks prior to randomization. Individuals
participating in observational studies are eligible.
- Have previously received topoisomerase 1 inhibitors or antibody drug conjugates
containing a topoisomerase inhibitor.
- Have an active second malignancy.
- Have active serious infection requiring antibiotics.
- Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or
Multicentric Castleman Disease.
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Has an active autoimmune disease that has required systemic treatment in the past 2
years.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.